Malcomson L, Dalal G, Vass C, Wright S, Gray E, Trenaman L, Payne K, Renehan A. Introducing PrefCoRe: quantifying and implementing patient preferences for the treatment of high-risk rectal cancer, including the new strategy of organ preservation. Poster presented at the 2020 Association of Coloproctology (ACPGBI) Virtual Conference; July 2020. [abstract] Colorectal Dis. 2020 Jul; 22(S1):41-2.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Njue AI, Prichard RK. Efficacy of ivermectin in calves against a resistant Cooperia oncophora field isolate. Parasitol Res. 2004 Aug 1;93(5):419-22.